Q3 2025 Outlook Report | Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
Explore advanced oncology forecasting strategies in our latest eBook—covering treatment pathways, biomarker segmentation, PD-1 therapies, and more. Download now| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Discover how a clinical-stage biotech partnered with J+D Forecasting to transform its oncology forecasting—accelerating Phase III launch readiness, building internal capability, and enabling strategic pipeline decisions with Onco+.| Evaluate
This one-page guide highlights five expert tips tohelp you navigate the unique challenges of oncology forecasting withgreater confidence.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
